Last reviewed · How we verify
Gutron® treatment
Gutron treatment works by inhibiting the reabsorption of bile acids in the ileum.
Gutron treatment works by inhibiting the reabsorption of bile acids in the ileum. Used for Hypercholesterolemia.
At a glance
| Generic name | Gutron® treatment |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Bile acid sequestrant |
| Target | Apical sodium-dependent bile acid transporter (ASBT) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
This leads to a reduction in cholesterol levels in the blood, which can help to lower the risk of cardiovascular events. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of the apical sodium-dependent bile acid transporter (ASBT).
Approved indications
- Hypercholesterolemia
Common side effects
- Constipation
- Nausea
- Diarrhea
Key clinical trials
- RaGuS Trial by Postoperative Patients (PHASE4)
- Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gutron® treatment CI brief — competitive landscape report
- Gutron® treatment updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI